AstriVax Rounds Out Executive Team with Chief Business Officer (CBO) Dr. Gregory Fanning
19 mars 2024 02h00 HE
|
AstriVax
Dr. Fanning brings a wealth of experience in creating infectious disease pipelines by internal R&D and licensing As the CBO of AstriVax, he will lead the company’s business development, including...
Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones
05 janv. 2024 16h01 HE
|
Barinthus Biotherapeutics
Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones
AstriVax Awarded €3 Million Grant to Advance therapeutic Hepatitis B Vaccine
12 déc. 2023 01h00 HE
|
AstriVax
The government grant is awarded by Flanders Innovation & Entrepreneurship (VLAIO).The grant will be used to accelerate the development of the company’s therapeutic vaccine targeting chronic...
Assembly Biosciences to Present New Data at AASLD The Liver Meeting®
11 oct. 2023 08h00 HE
|
Assembly Biosciences, Inc.
-- One poster and one oral presentation selected, with the poster highlighting new preclinical data from the Company’s interferon-α receptor agonist program -- SOUTH SAN FRANCISCO, Oct. 11, 2023 ...
Assembly Biosciences to Highlight Pipeline Progress in HBV and HDV at the 2023 International HBV Meeting
19 sept. 2023 16h05 HE
|
Assembly Biosciences, Inc.
-- Two oral presentations and one poster will feature new data from the Company’s hepatitis B/hepatitis D entry inhibitor, capsid assembly modulator ABI-4334, and interferon-alpha receptor agonist...
Assembly Biosciences Reports Second Quarter 2023 Financial Results and Recent Updates
09 août 2023 16h05 HE
|
Assembly Biosciences, Inc.
Herpesvirus candidate ABI-5366 anticipated to enter clinic in first half of 2024New data for several pipeline programs presented at IHW and EASL 2023Additional development candidate nomination...
Center for Disease Analysis Foundation Announces Receipt of an $8 Million Grant from Gilead Sciences to Relink Hepatitis B and C Patients to Care in the United States
20 juil. 2023 12h00 HE
|
CDA Foundation
LAFAYETTE, Colo., July 20, 2023 (GLOBE NEWSWIRE) -- The Center for Disease Analysis Foundation (CDA Foundation) announced today that it received an $8 million grant from Gilead Sciences (Nasdaq:...
Hepatitis B Vaccine Market Size To Surpass USD 12.36 Billion By 2030, exhibiting A CAGR Of 5.7%
17 juil. 2023 07h06 HE
|
Fortune Business Insights
Pune, India, July 17, 2023 (GLOBE NEWSWIRE) -- According to Fortune Business Insights, the global Hepatitis B Vaccine Market size was valued at USD 7.94 billion in 2022 and is projected to grow from...
Vaccitech to Present Positive Final Data at EASL Congress for Phase 1b/2 HBV002 Study in Adults with Chronic Hepatitis B
21 juin 2023 09h03 HE
|
Vaccitech plc
Meaningful, durable reductions of HBsAg were seen, both in participants who received VTP-300 alone and in combination with a low-dose PD-1 inhibitorTwo patients developed a non-detectable HBsAg level,...
Assembly Biosciences Presents New Data Highlighting Entry Inhibitor and Core Inhibitor Programs at EASL’s International Liver Congress™ 2023
21 juin 2023 08h00 HE
|
Assembly Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., June 21, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral...